Sugi Predict

Sugi Predict / Compounds / SCHEMBL1787367

SCHEMBL1787367

SCHEMBL1787367

CCc1ccc(-c2c(-c3ccccc3F)oc3ncnc(O[C@@H]4CCCN(CCCC(=O)OC)C4)c23)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNK2 Q07912 8/20 0.36
▸ LCK P06239 7/20 0.36
▸ CHRNB4 P30926 2/20 0.35
▸ CHRNA3 P32297 2/20 0.35
▸ CHRNB2 P17787 1/20 0.35
▸ CHRNA4 P43681 1/20 0.35
▸ EGFR P00533 2/20 0.35
▸ JAK2 O60674 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ ZAP70 P43403 1/20 0.34
▸ JAK3 P52333 1/20 0.34
▸ MERTK Q12866 2/20 0.33
▸ AURKA O14965 1/20 0.33
▸ SGK1 O00141 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1787145 0.93 CHRNB4 (0.38) TNK2LCKCHRNB4CHRNA3CHRNB2
SCHEMBL14467158 0.93 CHRNB4 (0.38) TNK2LCKCHRNB4CHRNA3CHRNB2
SCHEMBL1787517 0.93 EGFR (0.35) TNK2LCKCHRNB4CHRNA3CHRNB2
SCHEMBL1787239 0.93 KDM4E (0.41) TNK2LCKCHRNB4CHRNA3CHRNB2
SCHEMBL14467476 0.93 KDM4E (0.41) TNK2LCKCHRNB4CHRNA3CHRNB2
SCHEMBL1784266 0.91 TNK2 (0.43) TNK2LCKEGFRJAK2SRC
SCHEMBL1786857 0.91 TNK2 (0.43) TNK2LCKEGFRJAK2SRC
Formic Acid SCHEMBL1787516 0.91 CHRNB4 (0.36) TNK2LCKCHRNB4CHRNA3CHRNB2
SCHEMBL13271844 0.87 CHRNB4 (0.38) TNK2LCKCHRNB4CHRNA3CHRNB2
SCHEMBL1785560 0.86 KDM4E (0.40) TNK2LCKCHRNB4CHRNA3CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324222-B2 Cyclically substituted furopyrimidine derivatives and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-12-04 — — US disclosed
US-8324222-B2 Cyclically substituted furopyrimidine derivatives and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-12-04 — — US disclosed
US-8324222-B2 Cyclically substituted furopyrimidine derivatives and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-12-04 — — US disclosed
US-20110124665-A1 Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-05-26 — — US disclosed
US-20110124665-A1 Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-05-26 — — US disclosed
US-20110124665-A1 Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-05-26 — — US disclosed
WO-2007079861-A1 NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2007-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124665-A1 Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof DPYD, TK2, TPMT TNK2 1169/4885LCK 840/4885CHRNB4 4839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.